X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA SANOFI INDIA ELDER PHARMA/
SANOFI INDIA
 
P/E (TTM) x -0.2 37.1 - View Chart
P/BV x 0.1 7.0 1.4% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ELDER PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
SANOFI INDIA
Dec-17
ELDER PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3804,945 7.7%   
Low Rs1883,901 4.8%   
Sales per share (Unadj.) Rs491.21,081.8 45.4%  
Earnings per share (Unadj.) Rs-3.2141.6 -2.2%  
Cash flow per share (Unadj.) Rs14.4185.9 7.7%  
Dividends per share (Unadj.) Rs033.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs376.5868.8 43.3%  
Shares outstanding (eoy) m20.5423.03 89.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.1 14.1%   
Avg P/E ratio x-89.331.2 -285.7%  
P/CF ratio (eoy) x19.723.8 82.9%  
Price / Book Value ratio x0.85.1 14.8%  
Dividend payout %023.3 0.0%   
Avg Mkt Cap Rs m5,833101,862 5.7%   
No. of employees `000NA3.2 0.0%   
Total wages/salary Rs m2,1793,685 59.1%   
Avg. sales/employee Rs ThNM7,691.9-  
Avg. wages/employee Rs ThNM1,137.7-  
Avg. net profit/employee Rs ThNM1,006.5-  
INCOME DATA
Net Sales Rs m10,08924,914 40.5%  
Other income Rs m257807 31.8%   
Total revenues Rs m10,34625,721 40.2%   
Gross profit Rs m-7925,372 -14.7%  
Depreciation Rs m3611,022 35.4%   
Interest Rs m2,75611 25,057.3%   
Profit before tax Rs m-3,6535,146 -71.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,886 6.6%   
Profit after tax Rs m-653,260 -2.0%  
Gross profit margin %-7.821.6 -36.4%  
Effective tax rate %-3.436.6 -9.3%   
Net profit margin %-0.613.1 -5.0%  
BALANCE SHEET DATA
Current assets Rs m9,24014,432 64.0%   
Current liabilities Rs m9,9986,010 166.4%   
Net working cap to sales %-7.533.8 -22.2%  
Current ratio x0.92.4 38.5%  
Inventory Days Days4661 76.0%  
Debtors Days Days6028 210.5%  
Net fixed assets Rs m10,1247,991 126.7%   
Share capital Rs m206230 89.3%   
"Free" reserves Rs m5,58219,778 28.2%   
Net worth Rs m7,73420,008 38.7%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88227,770 82.4%  
Interest coverage x-0.3468.8 -0.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.9 49.1%   
Return on assets %11.811.8 99.8%  
Return on equity %-0.816.3 -5.2%  
Return on capital %22.325.8 86.6%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3076,306 4.9%   
Fx outflow Rs m1255,257 2.4%   
Net fx Rs m1811,049 17.3%   
CASH FLOW
From Operations Rs m11,7544,351 270.1%  
From Investments Rs m-561-787 71.2%  
From Financial Activity Rs m-6,762-1,884 358.9%  
Net Cashflow Rs m4,4321,680 263.8%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 7.5 14.4 52.1%  
FIIs % 16.8 14.6 115.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 10.5 343.8%  
Shareholders   16,479 15,184 108.5%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS